Kremers Urban Pharmaceuticals Inc. is aggressively pursuing both in-licensing generic drug products and internal research and development.

The Company seeks strategic alliances in the development of products and drug delivery technologies that would further enhance our capabilities or offerings. With a history of marketing products with high barrier to entry, the strategy is to complement the existing
Kremers Urban portfolio, which includes products such as Oxybutynin Chloride Extended-Release Tablets USP, Omeprazole
Delayed-Release Capsules USP, Nifedipine Extended-Release Tablets USP, Temozolomide Capsules, and Verapamil Extended-Release Capsules (PM).

To discuss strategic partnering opportunities, please contact:

Michael Block
Director of Business Development

Lannett Company, Inc.
13200 Townsend Rd
Philadelphia, PA 19154
Phone (215) 333-9000
Email mblock@lannett.com